ClinicalTrials.gg
RecruitingNCT06399263SPANYAUpdated Mar 3, 2026

Study of Psilocybin for Anorexia in Young Adults

A Phase 2 interventional study of Psilocybin and Preparation and Integration Sessions in Anorexia Nervosa, sponsored by Marissa Raymond-Flesch, MD, MPH. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Marissa Raymond-Flesch, MD, MPH · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 174 studies in Anorexia Nervosa with a site in United States — 36 open to participants now, 45 under way, none of them phase 3. Anorexia Nervosa · United States.

Planned enrollment
71st of 143
40 · median 40
Started
2024
with 12 others
Phase 2
20 of 174
5 open now
Primary completion
2029-11
later than 39 of 44 live
Registered
153rd of 174
by date

Among the 174 studies in Anorexia Nervosa with a site in United States, this one is the 71st largest by planned enrollment of the 143 interventional ones that give a count, is one of 13 that started in 2024, is one of 20 in phase 2, reaches primary completion later than 39 of the 44 other live ones, and was the 153rd registered.

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

36 of the 174 studies in Anorexia Nervosa with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 174 studies in Anorexia Nervosa with a site in United States, or all of them as a file.
02

Study summary

This is a single site trial of psilocybin therapy for the treatment of refractory Anorexia Nervosa in young adults. The psilocybin therapy will include three preparatory sessions, psilocybin dosing session one (20mg), two integration sessions, psilocybin dosing session two (up to 25mg), and three final integration sessions. Eating disorder symptoms will be measured pre and post treatment. One to two family member(s) of each young adult participant will be enrolled in the study. One of which will be required to attend a portion of two preparatory sessions and a portion of two integration sessions and receive psychoeducation about supporting the young adult participant through preparation and integration for psilocybin therapy. Investigators hypothesize that psilocybin will increase cognitive flexibility and that this increase will predict long-term changes in cognitive rigidity, habitual eating, and exercise behaviors in patients with Anorexia Nervosa.

03

Conditions studied

  • Anorexia Nervosa

Browse trials for

04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand and provide .
  • Between 18 and 25 years old at time of screening.
  • Meets Diagnostic and Statistical Manual () criteria for any type of Anorexia Nervosa
  • Currently experiencing symptoms of Anorexia Nervosa
  • Comfortable reading and writing in English
  • Have no anticipated changes in medication or surgical procedures for trial duration
  • Commit to attend all in-person and remote study visits and participate in all data collection procedures
  • Able to identify one or two family members or close friends to co-enroll in the study, who will be required to participate in select therapy sessions.
  • Agree to use a highly effective form of for two weeks prior to starting the study and one month after finishing the study.
  • Agree that for one week preceding each psilocybin session, they will refrain from taking any nonprescription medication, nutritional supplement, or herbal supplement except when approved by the research team. Exceptions will be evaluated by the research team and will include acetaminophen, non-steroidal anti-inflammatory drugs, and common doses of vitamins and minerals.
  • Agree to consume approximately the same amount of caffeine-containing beverages (e.g., coffee, tea) that they usually consume before arriving at the research unit on the mornings of psilocybin administration sessions. If the young adult participant does not routinely consume caffeinated beverages, they must agree not to do so prior to psilocybin administration sessions.

Exclusion criteria

Exclusion Criteria:

  • Current known pregnancy or positive pregnancy test at any time during the study
  • Personal history of bipolar disorder, or psychotic disorder verified by the Structured Clinical Interview for (SCID) and medical history at screening
  • less than 12 at screening
  • Unstable vital signs including Blood Pressure, Heart Rate, or Temperature
  • Abnormal Safety Labs including sodium, potassium, magnesium, phosphorus, creatinine, estimated , Aspartate Transferase,
  • abnormalities
  • Hospitalization or participation in a residential program for more than 2 of the past 4 weeks at the time of screening.
  • Unwilling to abstain from alcohol, Cannabidiol (CBD), tetrahydrocannabinol (THC), marijuana, and illicit drug use for 48 hours pre and post psilocybin dosing days and abstain from nicotine for 10 hours pre and post psilocybin dosing.
  • Positive urine toxicology testing for amphetamines, benzodiazepines, cocaine, cannabis, 3,4-Methylenedioxymethamphetamine (MDMA), and opioids (including methadone and buprenorphine) on the morning of either psilocybin administration session.
  • History of cardiovascular disease
  • Uncontrolled endocrine conditions, including diabetes, hyper or hypothyroidism
  • Significant and uncontrolled gastrointestinal illness at the discretion of the investigator
  • Significant and uncontrolled neurological disease including uncontrolled seizure disorder at the discretion of the investigator
  • Use of any prohibited concomitant medications or inability or unwillingness to discontinue according to the study's prescribed medication taper or tapering with the participants primary prescriber.
  • Needle phobia.
  • Simultaneous enrollment in another clinical trial.
  • Pregnant or Breast feeding.
  • Allergy or intolerance to any of the materials contained in the drug product
  • History of severe reaction to psychedelics at the discretion of the investigators.
  • High risk of self-harm/suicide
  • Mental health condition that will prevent engagement with the treatment team.
  • Unwilling or unable to participate in the treatment protocol as planned, including hydration with sports drinks on dosing days.
  • If any study physician feels that it would be unsafe to continue for any mental, physical or other reason
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Psilocybin Therapy

    The psilocybin therapy will include three preparatory sessions, psilocybin dosing session one (20mg), two integration sessions, psilocybin dosing session two (up to 25mg), and four final integration sessions

    Drug: Psilocybin · Behavioral: Preparation and Integration Sessions

Interventions

  • The psilocybin will include two dose administration sessions, first a 20mg administration, and second an administration of up to 25mg.

    Also known as: PEX010

  • BehavioralPreparation and Integration Sessions

    The psilocybin therapy will include three preparatory sessions, two dose A integration sessions, and four final integration sessions.

    Also known as: Psilocybin Therapy

06

What researchers measure

Primary outcomes

  1. Eating Disorder Examination (EDE)

    The EDE assess eating disorder behaviors and attitudes though an interviewer administered questionnaire. It provides 4 subscale scores (Restraint, Eating Concern, Shape Concern and Weight Concern). Score range from 0 to 6 and are averaged to calculate a global score. Higher scores indicate increased eating disorder thoughts and behaviors.

    Time frame: Baseline, 28 days, 90 days, 365 days

07

Study locations

1 of 2 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Nov 2029, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2024
First posted
May 3, 2024
StartActual
Nov 18, 2024
Primary completionEst.
Nov 2029
CompletionEst.
Nov 2029
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06399263
Lead sponsor
Marissa Raymond-Flesch, MD, MPH
Responsible party
Marissa Raymond-Flesch, MD, MPH (Professor, Pediatrics, University of California, San Francisco) — Sponsor-investigator
First posted
May 3, 2024
Start date
Nov 18, 2024
Primary completion
Nov 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Mar 3, 2026

Study contacts

Lisa Fredenburg, MS
Contact
psilocybin.an.study@ucsf.edu
415-993-2486
Marissa Raymond-Flesch, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion